Roche’s Genentech unit makes Ashley Magargee permanent CEO

14 Dec 2023
firstwordpharma.com
Executive Change
Roche’s Genentech unit recently said that Ashley Magargee will assume the position of CEO on a permanent basis from the start of 2024. Magargee added the interim chief executive responsibilities to her role earlier this year following the departure of Alexander Hardy.
Magargee joined Genentech in 2004 and has held senior management positions in lifecycle management, digital customer experience and market access, most recently serving as head of commercial portfolio. Roche CEO Teresa Graham noted that Magargee’s “career…spans the breadth of our business,” adding “I personally value her deep commitment to our people and strong regard for the stakeholders.”
Hardy left Genentech in November to be named as CEO of BioMarin, having previously worked at Novartis, PathoGenesis and GSK. Hardy joins the growing rank of ex-Genentech CEOs who have left to pursue chief executive roles at other biopharma firms, including Pascal Soriot to AstraZeneca, Art Levinson to Calico and Bill Anderson to Bayer.
For further analysis, read Vital Signs: The Roche management diaspora- where are they now?
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.